Floatz logo

Trametinib

Thyroid Gland Papillary Carcinoma

Cancer Research UKSmall moleculePhase 2/3Active
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
41/ 100
Competitive Position
95/ 100

Competitive context

15 Active assets in the Thyroid Gland Papillary Carcinoma cohort.

Asset / SponsorPhaseRating
Sorafenib
National Cancer Institute (NCI)
Phase 2B
Dabrafenib
Cancer Research UK
Phase 2/3B
Cobimetinib
Cancer Research UK
Phase 2/3B
VEMURAFENIB
Cancer Research UK
Phase 2/3CCC
ALECTINIB
Hoffmann-La Roche
Phase 2CCC

View all 30 →

Same molecule, other indications

Trametinib is also rated in:

melanomaActive
BB
Indicative · Phase 4
69 / 100
View asset →
anaplastic pleomorphic xanthoastrocytomaActive
BB
Indicative · Phase 4
69 / 100
View asset →
anaplastic oligodendrogliomaActive
BB
Indicative · Phase 4
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →